Current progress in the prediction of chemosensitivity for breast cancer

Breast Cancer

Volumn 11, Issue 1, 2004, Pages 42-48

  Shimizu, Daisuke ^a,c   Ishikawa, Takashi ^b   Ichikawa, Yasushi ^a   Toga, Shinji ^a   Hayasizaka, Yoshihide ^c   Okazaki, Yasushi ^d   Shimada, Hiroshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c RIKEN YOKOHAMA INSTITUTE   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; Chemotherapy; Drug sensitivity test; Microarray

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BREAST TUMOR; DNA MICROARRAY; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETIC MARKER; GENETICS; HUMAN; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; REVIEW; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENETIC MARKERS; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 1542289923     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02968001     Document Type: Article

References (21)

1. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC: Phase Ill trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (El193): J Clin Onco1 21:588-592, 2003. (Pubitemid 46621890)
2. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17:2355-2364, 1999. (Pubitemid 29368233)
3. Oshanghnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, open-label, phase I trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/ metastatic breast cancer. Ann Onco1 12:1247-1254, 2001. (Pubitemid 32994752)
4. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998. (Pubitemid 28363030)
5. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Result from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of the National Cancer Institute Monographs 30:96-102, 2001.
6. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H, Nagura H, Ogawa N, Hoffman RM, and the Chemosensitivity Study group for the Histoculture Drug-Response Assay: Potential of the Histoculture Drug-Response Assay to contribute to cancer patient survival. Clin Can Res 1:1537-1543, 1995. (Pubitemid 26028089)
7. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: earbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998. (Pubitemid 28439960)
8. Park K, Kim J, Lira S, Hart S: Topoisomerase I-alpha (topoll) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39:631-634, 2003. (Pubitemid 36287375)
9. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3:593-600, 1997. (Pubitemid 27211838)
10. Billgren AM, Rutqvist LE, Tani E, Wilking N, Fornander T, Skoog L: Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relapse-free survival. Acta Onco138:597-601, 1999. (Pubitemid 29333740)
11. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002. (Pubitemid 34130608)
12. Softie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874, 2001. (Pubitemid 32878711)
13. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN: A gene expression database for the molecular pharmacology of cancer. Nature Genetics 24:236-244, 2000. (Pubitemid 30132190)
14. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62:1139-1147, 2002. (Pubitemid 34160300)
15. Ichikawa Y, Ishikawa T, Takahashi S, Hamaguchi Y, Morita T, Nishizuka I, Yamaguchi S, Endo I, Ike H, Togo S, Oki S, Shimada H, Kadota K, Nakamura S, Goto H, Nitanda H, Satomi S, Sakai T, Narita I, Gejyo F, Tomaru Y, Shimizu K, Hayashizaki Y, Okazaki Y: Identification of genes regulating colorectal carcinogenesis by using the algorithm for diagnosing malignant state method. Biochem Biophys Res Commun 296:497-506, 2002.
16. Nishizuka I, Ishikawa T, Hamaguchi Y, Kamiyama M, Ichikawa Y, Kadota K, Miki R, Tomaru Y, Mizuno Y, Tominaga N, Yano R, Goto H, Nitanda H, Togo S, Okazaki Y, Hayashizaki Y, Shimada H: Analysis of gene expression involved in brain metastasis from breast cancer using cDNA microarray. Breast Cancer 9:26-32, 2002.
17. Morita T, Togo S, Kubota T, Kamimukai N, Nishizuka I, Kobayashi T, Ichikawa Y, Ishikawa T, Takahashi S, Matsuo K, Tomaru Y, Okazaki Y, Hayashizaki Y, Shimada H: Mechanism of postoperative liver failure after excessive hepatectomy investigated using a cDNA microarray. J Hepatobiliary Pancreat Surg 9:352-359, 2002. (Pubitemid 35000478)
18. Kadota K, Miki R, Bono H, Shimizu K, Okazaki Y, Hayashizaki Y: Preprocessing implementation for microarray (PRIM): an efficient method for processing cDNA microarray data. Physiol Genomics 4:183-188, 2001. (Pubitemid 33676694)
19. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV: Monitoring the expression Profiles of Doxorubicininduced and Doxorubicin-resistant Cancer Cells by cDNA Microarray. Cancer Res 60:4161-4166, 2000. (Pubitemid 30636599)
20. Kaufrnann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Onco121:2600-2608, 2003. (Pubitemid 46606344)
21. Pusztai L, Ayers M, Simmans FW, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi GN, Stec J: Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/ FAC chemotherapy in breast cancer. ASCO abstract 1, 2003.